JPMorgan Chase & Co. Cuts Ascentage Pharma Group International (NASDAQ:AAPG) Price Target to $33.00

Ascentage Pharma Group International (NASDAQ:AAPG) had its target price dropped by stock analysts at JPMorgan Chase & Co. from $46.00 to $33.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 126.80% from the stock’s previous close.

Several other research firms also recently commented on AAPG. BTIG Research reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $44.75.

Ascentage Pharma Group International Trading Down 2.6%

AAPG traded down $0.39 during mid-day trading on Thursday, reaching $14.55. 11,982 shares of the company traded hands, compared to its average volume of 6,862. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. Ascentage Pharma Group International has a 52-week low of $14.46 and a 52-week high of $38.58. The company’s fifty day moving average price is $16.83 and its 200-day moving average price is $19.41.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. On average, analysts predict that Ascentage Pharma Group International will post -2.42 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.